Cell therapy · developed by Prokidney
Rilparencel (Renal Autologous Cell Therapy, REACT) is an autologous cell therapy made from a patient's own kidney biopsy tissue and injected into the kidneys. It is being studied in chronic kidney disease and in type 2 diabetes mellitus.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05286853 | Phase 3 | Type 2 Diabetes Mellitus | Withdrawn | PROK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic Kidney DiseasesType 2 Diabetes Mellitus
Updated Oct 25, 2026. Something wrong or missing? Report it on the PROK page.
See PROK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PROK catalysts and pipeline →